RBF Capital’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

RBF Capital’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-10,924	Closed	-$36K	–	403
2019 Q3	$36K	Hold	10,924	–	–	﹤0.01%	376
2019 Q2	$54K	Hold	10,924	–	–	0.01%	383
2019 Q1	$68K	Hold	10,924	–	–	0.01%	367
2018 Q4	$37K	Hold	10,924	–	–	﹤0.01%	394
2018 Q3	$71K	Hold	10,924	–	–	0.01%	391
2018 Q2	$86K	Buy	+10,924	New	+$158K	0.01%	367

Other funds holding JNCE

TGI

TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

RBF Capital's JNCE Position: Q4 2019 in Review

RBF Capital sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q4 2019, closing a stake of 10,924 shares — an estimated $36K sold.

RBF Capital first reported a position in JNCE in Q2 2018 and held it in 6 quarters. The position peaked at $86K in Q2 2018. 100 funds tracked by Wall St. Rank hold JNCE as of Q4 2019.

RBF Capital reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
RBF Capital sold 10,924 Jounce Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $36K.
RBF Capital first reported a position in Jounce Therapeutics, Inc. Common Stock in Q2 2018 and held it in 6 quarters.
RBF Capital's Jounce Therapeutics, Inc. Common Stock position peaked at $86K in Q2 2018.
100 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q4 2019.

Based on RBF Capital's 13F filing for Q4 2019, filed 13 Feb 2020.